Show simple item record

dc.creatorMagadum, Ajit
dc.creatorKishore, Raj
dc.date.accessioned2021-03-15T15:49:06Z
dc.date.available2021-03-15T15:49:06Z
dc.date.issued2020-11-19
dc.identifier.citationMagadum, A.; Kishore, R. Cardiovascular Manifestations of COVID-19 Infection. Cells 2020, 9, 2508. https://doi.org/10.3390/cells9112508
dc.identifier.issn2073-4409
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/6210
dc.identifier.urihttp://hdl.handle.net/20.500.12613/6228
dc.description.abstractSARS-CoV-2 induced the novel coronavirus disease (COVID-19) outbreak, the most significant medical challenge in the last century. COVID-19 is associated with notable increases in morbidity and death worldwide. Preexisting conditions, like cardiovascular disease (CVD), diabetes, hypertension, and obesity, are correlated with higher severity and a significant increase in the fatality rate of COVID-19. COVID-19 induces multiple cardiovascular complexities, such as cardiac arrest, myocarditis, acute myocardial injury, stress-induced cardiomyopathy, cardiogenic shock, arrhythmias and, subsequently, heart failure (HF). The precise mechanisms of how SARS-CoV-2 may cause myocardial complications are not clearly understood. The proposed mechanisms of myocardial injury based on current knowledge are the direct viral entry of the virus and damage to the myocardium, systemic inflammation, hypoxia, cytokine storm, interferon-mediated immune response, and plaque destabilization. The virus enters the cell through the angiotensin-converting enzyme-2 (ACE2) receptor and plays a central function in the virus’s pathogenesis. A systematic understanding of cardiovascular effects of SARS-CoV2 is needed to develop novel therapeutic tools to target the virus-induced cardiac damage as a potential strategy to minimize permanent damage to the cardiovascular system and reduce the morbidity. In this review, we discuss our current understanding of COVID-19 mediated damage to the cardiovascular system.
dc.format.extent21 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartCells, Vol. 9, Issue 11
dc.relation.isreferencedbyMDPI
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectAngiotensin converting enzyme-2
dc.subjectCardiovascular disease
dc.subjectMyocardial injury
dc.subjectCytokine storm and inflammation
dc.titleCardiovascular Manifestations of COVID-19 Infection
dc.typeText
dc.type.genreJournal article
dc.contributor.groupCenter for Translational Medicine (Temple University)
dc.description.departmentPharmacology
dc.relation.doihttps://doi.org/10.3390/cells9112508
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeLewis Katz School of Medicine
dc.creator.orcidMagadum|0000-0001-7298-8255
dc.creator.orcidKishore|0000-0002-8168-3004
dc.temple.creatorMagadum, Ajit
dc.temple.creatorKishore, Raj
refterms.dateFOA2021-03-15T15:49:06Z


Files in this item

Thumbnail
Name:
Magadum-JournalArticle-2020-11.pdf
Size:
1.481Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY